Company
Headquarters: Berlin, Germany
Employees: 300
CEO: Mr. Matthias Gaertner
€321.9 Million
EUR as of July 1, 2025
US$380.1 Million
| Company | Market Cap (USD) |
|---|---|
| McKesson Corporation | $88.11 B |
| Cencora, Inc. | $56.44 B |
| Cardinal Health, Inc. | $38.66 B |
| Henry Schein, Inc. | $9.31 B |
| Shanghai Pharmaceuticals Holding Co. Ltd | $8.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
Medios AG has the following listings and related stock indices.
Stock: FSX: ILM1 wb_incandescent
Stock: XDUS: ILM1 wb_incandescent
Stock: XETR: ILM1 wb_incandescent